Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...

Descripción completa

Detalles Bibliográficos
Autor principal: Zanon, Ezio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536392/
https://www.ncbi.nlm.nih.gov/pubmed/37765002
http://dx.doi.org/10.3390/ph16091195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536392/
https://www.ncbi.nlm.nih.gov/pubmed/37765002
http://dx.doi.org/10.3390/ph16091195

Ejemplares similares